Skip to main content
NVDA-2.33%AAPL+3.12%GOOGL+0.37%MSFT+0.13%AMZN-0.10%TSM-1.05%SPCX+2.07%AVGO-0.48%META-0.84%TSLA-0.44%SKHY-3.77%MU-4.62%BRK-B-0.27%LLY+0.45%JPM-0.57%WMT+0.03%AMD-3.08%V-0.15%XOM+0.59%ASMLa-1.66%JNJ-0.10%INTC-4.85%MA-0.51%0700.HK-1.94%1398.HK+0.79%ORCL-3.65%ABBV+0.51%BAC-0.55%CSCO-1.25%CVX-0.29%COST-0.30%KO+0.61%LRCX-4.70%CAT-1.57%AP2d-1.55%0005.HK-0.78%AMAT-2.38%UNH-0.62%HSBA.L-1.30%DELL-3.68%PG+0.23%MS-0.91%GE-0.69%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.58%0939.HK+1.66%GS-0.91%NZDJPY-2.56%AUDJPY-1.81%CHFJPY-1.60%NZDCAD-1.40%EURNZD+1.40%GBPNZD+1.36%NZDUSD-1.31%USDJPY-1.29%GBPJPY-1.22%EURJPY-1.22%CADJPY-1.18%NZDCHF-1.00%USDZAR+0.93%USDNOK+0.84%EURZAR+0.83%USDSEK+0.82%AUDNZD+0.78%GBPZAR+0.76%EURNOK+0.74%EURSEK+0.71%AUDCAD-0.66%AUDDKK-0.63%EURAUD+0.61%GBPAUD+0.58%CHFNOK+0.57%USDTHB+0.56%CHFSEK+0.55%AUDUSD-0.54%AUDSGD-0.51%USDMXN+0.43%GBPTRY+0.41%CADCHF+0.40%NOKJPY-0.39%EURCHF+0.38%GBPCHF+0.36%NZDSGD-0.36%USDPLN+0.35%USDCHF+0.32%GBPHKD+0.32%GBPMXN-0.28%EURPLN+0.25%SGDJPY+0.23%USDSGD+0.22%AUDCHF-0.22%NZDMXN-0.17%USDILS+0.16%EURSGD+0.12%EURHKD-0.11%USDTRY+0.11%PLNJPY+0.11%USDDKK+0.11%AUDNOK+0.10%USDCAD-0.09%EURCZK-0.09%USDCNH+0.09%EURUSD+0.06%GBPUSD+0.06%GBPCAD-0.05%GBPSGD+0.05%CHFSGD-0.04%USDCOP-0.04%EURCAD-0.03%EURGBP+0.02%USDHKD+0.01%EURCNH0.00%EURDKK0.00%XPTUSD-5.60%UKOIL+5.27%USOIL+4.94%HG1-4.78%GAGUSD-4.56%XAGUSD-4.56%GAUUSD-1.03%XAUUSD-1.03%XNGUSD+0.99%COTTON+0.72%S1+0.67%W1+0.56%BTCUSD-1.18%ETHUSD+0.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-1.45%TRXUSDT+0.24%ZECUSDT-7.22%DOGEUSD-2.57%XMRUSDT-0.30%LINKUSD-0.93%XLMUSD-1.29%BCHUSDT-9.87%LTCUSD-1.49%UNIUSD-1.22%TONUSD+24.88%HBARUSDT-2.14%SUIUSD-3.57%TAOUSDT-4.58%AAVEUSD-2.14%DOTUSDT-1.20%ICPUSDT-1.26%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.03%ARBUSDT+0.12%JUPUSDT-3.82%INJUSDT-2.63%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-0.60%PYTHUSDT-0.94%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-2.81%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.28%IOTAUSDT-3.30%AXSUSDT-2.04%FARTCOINUSDT-3.53%EOSUSDT-2.41%DYDXUSDT-1.85%ORDIUSDT-0.60%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.33%AAPL+3.12%GOOGL+0.37%MSFT+0.13%AMZN-0.10%TSM-1.05%SPCX+2.07%AVGO-0.48%META-0.84%TSLA-0.44%SKHY-3.77%MU-4.62%BRK-B-0.27%LLY+0.45%JPM-0.57%WMT+0.03%AMD-3.08%V-0.15%XOM+0.59%ASMLa-1.66%JNJ-0.10%INTC-4.85%MA-0.51%0700.HK-1.94%1398.HK+0.79%ORCL-3.65%ABBV+0.51%BAC-0.55%CSCO-1.25%CVX-0.29%COST-0.30%KO+0.61%LRCX-4.70%CAT-1.57%AP2d-1.55%0005.HK-0.78%AMAT-2.38%UNH-0.62%HSBA.L-1.30%DELL-3.68%PG+0.23%MS-0.91%GE-0.69%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.58%0939.HK+1.66%GS-0.91%NZDJPY-2.56%AUDJPY-1.81%CHFJPY-1.60%NZDCAD-1.40%EURNZD+1.40%GBPNZD+1.36%NZDUSD-1.31%USDJPY-1.29%GBPJPY-1.22%EURJPY-1.22%CADJPY-1.18%NZDCHF-1.00%USDZAR+0.93%USDNOK+0.84%EURZAR+0.83%USDSEK+0.82%AUDNZD+0.78%GBPZAR+0.76%EURNOK+0.74%EURSEK+0.71%AUDCAD-0.66%AUDDKK-0.63%EURAUD+0.61%GBPAUD+0.58%CHFNOK+0.57%USDTHB+0.56%CHFSEK+0.55%AUDUSD-0.54%AUDSGD-0.51%USDMXN+0.43%GBPTRY+0.41%CADCHF+0.40%NOKJPY-0.39%EURCHF+0.38%GBPCHF+0.36%NZDSGD-0.36%USDPLN+0.35%USDCHF+0.32%GBPHKD+0.32%GBPMXN-0.28%EURPLN+0.25%SGDJPY+0.23%USDSGD+0.22%AUDCHF-0.22%NZDMXN-0.17%USDILS+0.16%EURSGD+0.12%EURHKD-0.11%USDTRY+0.11%PLNJPY+0.11%USDDKK+0.11%AUDNOK+0.10%USDCAD-0.09%EURCZK-0.09%USDCNH+0.09%EURUSD+0.06%GBPUSD+0.06%GBPCAD-0.05%GBPSGD+0.05%CHFSGD-0.04%USDCOP-0.04%EURCAD-0.03%EURGBP+0.02%USDHKD+0.01%EURCNH0.00%EURDKK0.00%XPTUSD-5.60%UKOIL+5.27%USOIL+4.94%HG1-4.78%GAGUSD-4.56%XAGUSD-4.56%GAUUSD-1.03%XAUUSD-1.03%XNGUSD+0.99%COTTON+0.72%S1+0.67%W1+0.56%BTCUSD-1.18%ETHUSD+0.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-1.45%TRXUSDT+0.24%ZECUSDT-7.22%DOGEUSD-2.57%XMRUSDT-0.30%LINKUSD-0.93%XLMUSD-1.29%BCHUSDT-9.87%LTCUSD-1.49%UNIUSD-1.22%TONUSD+24.88%HBARUSDT-2.14%SUIUSD-3.57%TAOUSDT-4.58%AAVEUSD-2.14%DOTUSDT-1.20%ICPUSDT-1.26%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.03%ARBUSDT+0.12%JUPUSDT-3.82%INJUSDT-2.63%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-0.60%PYTHUSDT-0.94%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-2.81%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.28%IOTAUSDT-3.30%AXSUSDT-2.04%FARTCOINUSDT-3.53%EOSUSDT-2.41%DYDXUSDT-1.85%ORDIUSDT-0.60%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
SL

SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ • Healthcare

$13.95
-$0.01 (-0.1%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$13.71
Previous Close$13.95
Day Range$13.71 - $14.33
Avg. Volume (3M)7.2M
Market Cap$2.5B
52 Week Range
$1.39$15.88
Next EarningsIn 62 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$32.4M
EPS (TTM)
-$0.21
ROA (TTM)
-22.33%
Current Ratio
18.83
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+21.0%Q1 2026-$0.05
+16.7%Q2 2026-$0.05
-11.1%Q3 2026-$0.05
Next

Nov 11

in 62 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -11.1%

Net income widened year over year for SELLAS Life Sciences Group in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026. The company posted a GAAP net loss of roughly $9.6 million, down 45.5% from a net loss of about $6.6 million a year ago, as it continued investing in its late-stage oncology immunotherapy programs such as galinpepimut-S (GPS) and nelipepimut-S. Operating income was about -$10.6 million, while EPS came in at -$0.05. Cash usage remained elevated, with negative operating cash flow of roughly $7.6 million for the quarter. For the next period, consensus calls for EPS of -$0.05.

View full earnings history

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a NASDAQ-listed healthcare company in the Biotechnology field that operates as a late-stage biopharmaceutical developer focused on novel cancer immunotherapies. In qualitative terms it is a small-cap biotech centered on oncology candidates, with its work concentrated in the United States.

Name
SELLAS Life Sciences Group, Inc.
CEO
Angelos Stergiou
Website
www.sellaslifesciences.com
Industry
Healthcare
Year Founded
2012
Employees
13

Today's Snapshot

AI-generated

SLS is trading 1.6% below yesterday's close, while its sector was flat. SELLAS faced an investigation by Pomerantz, an investor law firm, over delayed clinical-trial results.

Trading Volume

Below 10d avg (6.6M)

2.8M

vs S&P 500 Today

Underperforming Market

-1.02%

Updated: September 10, 2026 at 17:03 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
SLS presents a buy profile driven by a firm ADX that signals trend strength and confirmation from medium- and longer-term moving averages, while short-term averages are roughly inline with the current price suggesting consolidation. Momentum readings are neutral and on balance with a modest MACD, and VWAP sits just below the market, offering intraday support. Volatility is elevated by ATR and on-balance volume is soft, which argues for caution around moves. Technical takeaway: Buy — trend and multi-period moving-average support outweigh muted momentum and weak volume.
All signals
  • EMA (5 indicators)$7.69 - $13.79
    Buy
  • RSI (14)53.44
    Neutral
  • Stochastic %K (14, 3, 3)40.94
    Neutral
  • MACD Level (12, 26)0.46
    Neutral

Peers & Related Assets

OABIOmniAb, Inc.
$4.01-5.4%
CDXSCodexis, Inc.
$1.430.0%
GNFTGenfit S.A.
CCCCC4 Therapeutics, Inc.
PRLDPrelude Therapeutics Incorporated
IVVDInvivyd, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.